T2D cases-lacking nephropathy excluded T2D-associated SNPs. Nominal associations were tested in an additional 483 T2D-ESKD cases and 554 controls in the replication stage. Meta-analysis of 4218 discovery and replication samples revealed three significant associations with T2D-ESKD at CD2AP and MMP2 (P corr < 0.05 corrected for effective number of SNPs in each locus). Removal of APOL1 renal-risk genotype carriers revealed additional association at five loci, TTC21B, COL4A3, NPHP3-ACAD11, CLDN8, and ARHGAP24 (P corr < 0.05). Genetic variants at COL4A3, CLDN8, and ARHGAP24 were potentially pathogenic. Gene-based associations revealed suggestive significant aggregate effects of coding variants at four genes. Our findings suggest that genetic variation in kidney structure-related genes may contribute to T2D-attributed ESKD in the AA population.
Introduction
Relative to European Americans (EAs), African Americans (AAs) are at higher risk for developing end-stage kidney disease (ESKD). In 2012, the incidence rate of ESKD was 908 cases per million in AAs, nearly 3.3-fold higher than in EAs (USRDS 2014) . The excess rate of ESKD in AAs is partly explained by socioeconomic factors (Byrne et al. 1994; Freedman 2002) . Diabetes mellitus contributes to more than 44 % of all cases of ESKD in the US and approximately 90 % relate to type 2 diabetes (T2D) (USRDS 2014) . Familial aggregation of diabetic kidney disease (DKD), including ESKD attributed to T2D (T2D-ESKD), has been reported (Seaquist et al. 1989; Spray et al. 1995; Freedman et al. 1995; Quinn et al. 1996; Iyengar et al. 2015) . AAs with T2D who have T2D-ESKD affected relatives have a nearly eightfold higher risk for developing T2D-ESKD compared with those who lack relatives with T2D-ESKD. The association remains after controlling for income, education, serum cholesterol, smoking, and hypertension . In addition, prior genomewide association studies (GWAS) have identified variants associated with DKD in multiple populations (Maeda 2004; Pezzolesi et al. 2009; McDonough et al. 2011; Sandholm et al. 2012) . These findings suggest that genetic factors may play a role in the development of nephropathy and ESKD in T2D patients. While the apolipoprotein L1 gene (APOL1) explains a substantial proportion of the disparity in non-diabetic ESKD in AAs (Tzur et al. 2010; Genovese et al. 2010) , less is known about the genetic contributors to the high T2D-ESKD risk in AAs (Bonomo et al. 2014a; Ma et al. 2016; Skorecki and Wasser 2016) .
Structural abnormalities in the kidney, including glomerular basement membrane (GBM) thickening, podocyte effacement, mesangial matrix expansion, glomerulosclerosis, and tubulointerstitial fibrosis, are observed during the development of kidney disease in patients with diabetes (Badal and Danesh 2014) . A number of gene products play critical roles in maintaining normal kidney substructure and variants in several of these genes that have been associated with DKD. For example, three single nucleotide polymorphisms (SNPs) in the CD2-associated protein gene (CD2AP), essential for podocyte function, were associated with ESKD in Europeans with type 1 diabetes (T1D) (Hyvönen et al. 2013) . Coding variants in the podocyte slit diaphragm gene nephrin (NPHS1) were associated with T2D-ESKD in AAs (Bonomo et al. 2014b ). In addition, genetic variants at shroom family member 3 (SHROOM3), which plays a role in maintaining the integrity of the glomerular filtration barrier (Yeo et al. 2015) , and uromodulin (UMOD), a kidney-specific gene expressed in the thick ascending limb (TAL) of the loop of Henle, were associated with kidney filtration in Europeans with T2D (Deshmukh et al. 2013) .
These findings suggest that additional variants in glomerular and tubulointerstitial structure-related genes may be associated with ESKD in AAs with T2D. Herein, 47 candidate genes involved in kidney structure were examined using a high coverage genotyping array, with a customized content of the respective targeted regions, to evaluate the impacts of common and low-frequency SNPs for association with T2D-ESKD in 4885 AA subjects.
Materials and methods

Study samples and clinical characteristics
The discovery stage included 2041 AA participants with T2D-ESKD and 1140 AA controls without diabetes or nephropathy. The replication stage included 483 AA participants with T2D-ESKD and 554 AA controls without diabetes or nephropathy. Trait discrimination analyses included T2D-ESKD cases and controls from the discovery stage, as well as 667 AAs with T2D who lacked evidence of nephropathy (Table 1 ). All subjects resided in North Carolina, South Carolina, Georgia, Tennessee, and Virginia. Patients were considered to have T2D-ESKD when diabetes was diagnosed after age 25 years and was present for ≥5 years prior to the onset of ESKD (or in the presence of diabetic retinopathy ensuring adequate T2D durations), and one or more of the following: renal replacement therapy (N = 1928), estimated glomerular filtration rate (eGFR) <30 ml/min/1.73 m 2 (N = 43), or urine albumin:creatinine ratio (UACR) >300 mg/g (N = 70), when eGFR was missing. Patients with ESKD attributed to non-diabetic causes were excluded. Nondiabetic non-nephropathy controls included participants without diabetes or kidney disease (eGFR >60 ml/ min/1.73 m 2 and UACR <30 mg/g). Individuals with T2D-lacking nephropathy had eGFR ≥60 ml/min/1.73 m 2 and UACR <30 mg/g. Detailed descriptions of inclusion criteria for T2D-ESKD patients, non-diabetic non-nephropathy controls, and T2D-lacking nephropathy subjects are included in the Supplementary Methods. This study was approved by the Wake Forest School of Medicine Institutional Review Board. All participants provided written informed consent.
Selection of kidney structure-related candidate genes
Although the precise mechanisms underlying kidney disease progression in patients with T2D are unclear, dysfunction of the glomerular filtration barrier, mesangial cell proliferation, mesangial matrix expansion, renal tubular atrophy, and renal interstitial fibrosis are observed. Therefore, genes related to the structure or function of podocytes, the slit diaphragm, GBM, mesangial cells, mesangial matrix, renal tubules, and renal interstitium were selected. Kidney structure-related genes were selected based on literature search and online database queries of GeneCards and Online Mendelian Inheritance in Man (OMIM) using keywords, including "glomerular", "podocytes", "mesangial matrix", "glomerular basement membrane", and "renal tubular". A total of 47 genes reported to impact kidney structures were selected. These included NPHS1, NPHS2, CD2AP, and ACTN4 in podocytes/slit diaphragms (Fan et al. 2006) , type IV collagen, and LAMB2 in GBM (Miner 2011) , ITGA3 and MMP2 in mesangial matrix (Prete et al. 1997; Shukrun et al. 2014) , and SLC12A3, ATP6V1BA, and the claudin gene-family in renal tubules (Abu Seman et al. 2014; Brown et al. 2009; Yu 2015) (full list in Supplementary Table 1) .
Genotyping, imputation, and quality control
Discovery and trait discrimination samples
Samples from the discovery and trait discrimination stages (to discriminate association with nephropathy from association with T2D per se) were genotyped on a custom Affymetrix Axiom Biobank Genotyping Array (Affymetrix, Santa Clara, CA, USA). Detailed SNP information, custom content design, including fine mapping of candidate regions, genotyping methods, and quality control are described in the Supplementary Methods. The final data set consisted of 3848 subjects with relevant phenotypes for analysis. Relevant to this study, 4588 highly dense SNPs flanking 25-kb upstream and downstream of the 47 selected candidate genes which passed standard quality control (QC) were examined in the discovery stage.
Replication samples
483 AA T2D-ESKD cases and 554 AA controls (non-diabetic, non-nephropathy) were genotyped in the replication stage with the Affymetrix Genome-Wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA, USA). Standard quality controls (QCs) were applied to remove SNPs with call rate <95 %, minor allele frequency (MAF) <0.01, or showing departure from HWE (P < 1 × 10 −4 ). Sample QC was performed to remove subjects with call rates <95 %, contamination, duplicates, or population outliers. SNPs that passed QC were used for pre-phasing and imputation to the cosmopolitan reference haplotype panel from the 1000 Genomes Project phase 1 version 3 (March 2012) (1000 Genomes Project Consortium et al. 2010) using SHAPEIT2 (Delaneau et al. 2012 ) and IMPUTE2 (Marchini et al. 2007 ). Imputed variants with imputation info score <0.4 were removed.
Statistical analysis
Single-variant association
Single-variant association in case-control samples was performed using linear mixed models (LMM) implemented in the program MMM (Pirinen et al. 2013) under an additive genetic model with adjustment for age and gender (Baseline model). This method incorporated a genetic relationship matrix (GRM) estimated from a set of high-quality autosomal SNPs as a random effect to control for population structure and cryptic relatedness. Whole genome analysis of discovery samples with 516,226 SNPs that passed QC yielded an inflation factor of 1.02, suggesting that population structure was sufficiently controlled by including GRM as a random effect. In the discovery stage, 4588 genetic variants from 47 candidate gene regions were tested in 2041 AA T2D-ESKD cases and 1140 AA non-diabetic, non-nephropathy controls. Nominally significant SNPs (P < 0.05) were further analyzed in the discrimination stages.
To distinguish whether discovery stage associations were driven by T2D alone or T2D-ESKD, 667 AAs with T2D-lacking nephropathy were included in two trait discrimination analyses. First, association was assessed in 2041 AAs with T2D-ESKD versus 667 AAs with T2D-lacking nephropathy. Differences in the effect size between T2D-ESKD versus non-diabetic controls (discovery stage) and T2D-ESKD versus T2D alone (discrimination stage) analyses were tested using Cochran's Q-test implemented in METAL (Willer et al. 2010) . SNPs showing heterogeneity (Cochran's Q-test P < 0.05) and small effects (P > 0.05) in the T2D-ESKD versus T2D non-nephropathy analysis, suggesting lack of association with ESKD, were excluded. Second, the remaining SNPs were tested for association between the 667 AA T2D non-nephropathy participants versus the 1140 AA non-diabetic non-nephropathy controls. SNPs showing nominal association (P < 0.05) with T2D were excluded. These analyses removed SNPs that were solely associated with T2D. In secondary discrimination analyses, T2D samples without nephropathy that had T2D durations less than 5 years (N = 204) were removed to minimize misclassification.
SNPs remaining after the discovery and discrimination stages were further tested for replication in 483 AA T2D-ESKD cases and 554 AA controls-lacking diabetes and nephropathy. A meta-analysis was performed that included the discovery and replication cases and controls (N = 4885) using a fixed-effect inverse variance weighting method implemented in METAL (Willer et al. 2010 ).
Effective number of SNPs calculation
In each candidate region, the effective number of SNPs was calculated from the eigenvalues of the pair-wise SNP correlation matrix created with composite linkage disequilibrium (LD) for SNPs included in the discovery stage using simple M (Gao et al. 2008) . Meta-analysis results were corrected for the effective number of SNPs in each region given their candidacy for associations. A corrected p value (P corr ) <0.05 was considered significant.
Controlling for the effect of the apolipoprotein L1 gene (APOL1)
Two sets of variants in the APOL1 gene are strong predictors of non-diabetic kidney disease in AAs. To account for the confounding effect of APOL1, the same singlevariant analyses were repeated (APOL1-negative model) by removing 1019 APOL1 renal-risk-variant carriers and those missing APOL1 genotypes from T2D-ESKD, T2D non-nephropathy, and non-diabetic non-nephropathy groups, in both discovery and replication cohorts. Specifically, we removed 425 of 2041 T2D-ESKD cases, 293 of 1140 non-diabetic non-nephropathy controls, and 131 of 667 T2D non-nephropathy individuals from the discovery cohort. In addition, 100 of 483 T2D-ESKD cases and 70 of 554 non-diabetic non-nephropathy controls were removed from the replication cohort. Individuals were considered APOL1 renal-risk-variant carriers if they possessed two G1 alleles (rs60910145 G allele, rs73885319 G allele), two G2 alleles (6 base pair in-frame deletion), or were compound heterozygotes (one G1 and one G2 allele) (Genovese et al. 2010) . The power to detect odds ratio (OR) ≥1.50 for SNPs with an effect allele frequency ≥0.05 at α level = 1×10 −4 under an additive model fell from 68 to 50 % after removing APOL1 risk allele carriers (http://csg.sph.umich.edu// abecasis/cats/).
Gene-based association
Sequence kernel association test (SKAT) (Wu et al. 2011) and Madsen-Browning test (MB) (Madsen and Browning 2009) , implemented in RAREMETAL (Liu et al. 2014) , were used to perform gene-based analyses with GRM included as a random effect. Only loss of function (LOF) and missense variants for each region were aggregated which was based on annotations from variant effect predictor (VEP) (McLaren et al. 2010) . Candidate regions with only one variant were not tested. Age and gender were included as fixed-effect covariates. A p value <0.001, corrected for the number of genes tested, was considered statistically significant.
Bioinformatic characterization
Expression quantitative trait loci analysis
We identified proxies (r 2 > 0.8) for top associated variants using SNAP (https://www.broadinstitute.org/mpg/ snap/ldsearch.php) based on African population and 1000 Genome Project data. Top variants and their LD proxies were then searched in a publically available eQTL database GTEx (http://www.gtexportal.org/home/).
Comprehensive functional annotation
Comprehensive variant annotation was performed using whole-genome sequencing annotator (WGSA) through its Amazon Machine Image. WGSA incorporates functional annotation from ANNOVAR (Wang et al. 2010) , SnpEff (Cingolani et al. 2012) , and VEP (McLaren et al. 2010) using contigs from both RefSeq (Pruitt et al. 2014 ) and 1 3
Ensembl (Yates et al. 2016 ). In addition, it integrates five functional prediction scores, eight conservation scores, four disease-related annotations, and regulatory region-centric resources from multiple epigenomics projects.
Results
The impact of 4588 variants in 47 genes involved in kidney structure was investigated in 5 AA cohorts for associations with T2D-ESKD. Overall, 9 variants, 2 missense and 7 intronic, upstream, or downstream of candidate regions, located in 7 distinct regions reached locus-wide significance in either baseline model or APOL1-negative model.
Clinical characteristics of study participants
Characteristics of the samples in discovery, discrimination, and replication stages are shown in Table 1 . Clinical characteristics of the individuals in the discovery stage were similar to those in the replication stage. The average age at recruitment was greater for individuals with T2D-ESKD and T2D-lacking nephropathy, compared with nondiabetic non-nephropathy controls (P < 1 × 10 −27 in all stages). However, the average age of non-diabetic controls was greater than the average age at T2D diagnosis in T2D-ESKD cases (P < 1 × 10
).
Association analysis in discovery stage
The impact of 4588 variants in 47 genes involved in kidney structure (Supplementary Table 1 ) was tested in 2041 T2D-ESKD cases and 1140 non-diabetic non-nephropathy controls for association with T2D-ESKD using a linear mixed model-based method (stage 1, Fig. 1 ) (Sawcer et al. 2011; Pirinen et al. 2013 ). Age and gender were included as fixed effects (Baseline model). These analyses did not adjust for PC1 given that the effect of ancestry is accounted for by GRM. A secondary analysis was performed which removed APOL1 two-renal-risk-variant carriers, given their increased risk for non-diabetic kidney disease (APOL1-negative model). For single SNP analysis, only SNPs with MAF ≥0.01 were included. The number of SNPs in each gene region ranged from 11 to 205. The coverage for each of the 47 genes was calculated using SNPs with MAF ≥0.01 in 1000 Genome phase 1 version 3 AFR samples. The average coverage at r 2 > 0.5 (pair-wise LD) was 54.4 %, and varied from 27.6 to 92.8 %. Of 4588 SNPs, 212 showed nominal association (P < 0.05) in baseline model from 39 candidate regions; these were further examined in the discrimination stages.
Discrimination analysis
Two analyses were performed to differentiate T2D-ESKD loci identified in the discovery stage as putative ESKDassociated or T2D-associated loci. An independent cohort of 667 AA individuals with T2D-lacking nephropathy was compared with T2D-ESKD cases and with non-diabetic non-nephropathy controls from the discovery stage in separate analyses (Table 1 ). First, we tested for association of the 212 associated SNPs between 2041 AA T2D-ESKD cases and 667 AAs with T2D-lacking nephropathy (stage 2a). Cochran's Q-test (Willer et al. 2010 ) was used to test for differences in allelic effects of association results between stage 1 and stage 2a, assuming that SNPs associated with T2D-ESKD have similar effects in both analyses. The smaller sample size in stage 2a reduced power to detect significant associations. Of the 212 SNPs, 169 did not demonstrate significant heterogeneity in effect sizes in stage 1 and stage 2a (P het > 0.05). They were further tested for association with T2D by comparing 667 AA individuals with T2D-lacking nephropathy with 1140 AA non-diabetic non-nephropathy controls (stage 2b). Evidence of association with T2D was observed for three SNPs (P < 0.05); these were excluded from further analysis. The remaining 166 candidate SNPs from 35 distinct genomic regions were carried to the replication stage. Secondary discrimination analyses excluding T2D patients with <5 years disease duration yielded similar results (data not shown). 
Replication and meta-analysis
An independent cohort of 483 AA T2D-ESKD cases and 554 AA non-diabetic non-nephropathy controls with imputed dosage data was used to replicate the 166 SNPs selected from stage 2b (stage 3). All SNPs met QC criteria in the replication cohort. The average imputation quality score (info) was 0.90, with the lowest info score of 0.45. Ninety SNPs from 30 candidate regions showed consistent directions of association with T2D-ESKD. Meta-analysis was performed to combine association results from stage 1 and stage 3 (labeled 'stage 4'). Three SNPs reached locus-wide significance after correcting for the effective number of SNPs in the respective regions (P corr < 0.05) ( Table 2; Supplementary Table 2 , P corr = 0.060) located 13-kb downstream from SLC12A3 (Supplementary Table 3 ).
Association analyses excluding APOL1 renal-risk carriers
The same series of single-variant analyses were performed under APOL1-negative model after removing APOL1 renal-risk genotype carriers. A total of 70 SNPs showed evidence of association with T2D-ESKD (P < 0.05) and no evidence of association with T2D (stage 1 through stage 3). Meta-analysis of T2D-ESKD cases and non-nephropathy controls from the discovery and replication stages (stage 4) revealed six additional SNPs demonstrating locus-wide significance (Table 3; Supplementary Table 4 , P corr = 0.060) located exon 7 of WNK4 (Supplementary Table 3 ). All the three locus-wide significant SNPs from baseline model were no longer significant in APOL1-negative model (P corr > 0.05); despite similar effect sizes in baseline model and APOL1-negative model. This suggests that the attenuation of association may be due to decreased sample size with loss of power (Supplementary Table 5 ).
Gene-based analysis
To improve statistical power, gene-based analysis was performed to aggregate the effects of functional variants within each candidate region using samples from the discovery and discrimination stages. Only missense and loss of function (LOF) variants were considered, the latter are predicted to cause splice site changes, frameshifts, or stop codon gains (McLaren et al. 2010) . Initially, 2041 AA T2D-ESKD cases and 1140 AA non-diabetic non-nephropathy controls were examined in the discovery stage, followed by testing 2041 AA T2D-ESKD cases and 667 AAs with T2D-lacking nephropathy in the discrimination stage under baseline and APOL1-negative models. Analyses were performed for 39 genes with variant counts ≥2. After excluding genes showing association with T2D alone, no gene reached defined significance level (P < 0.001, correction for 39 comparisons). However, nominal associations were observed at EMP2 (variant count = 2, P = 0.0065), COL4A3 (variant count = 12, P = 0.0044), WNK4 (variant count = 8, P = 0.0081), and CLDN14 (variant count = 2, P = 0.0026) under APOL1-negative model (Table 4) .
Bioinformatic characterization
We applied expression quantitative trait loci (eQTL) analysis and functional annotation tool to uncover functional relevance underlying the identified associations. In the eQTL analysis, locus-wide significant SNPs from stage 4 and their proxies were queried in the publically available eQTL database GTEx. The intronic SNP rs10433935 in ARH-GAP24 was strongly associated with expression level of ARHGAP24 in artery-tibial tissue (P = 0.000011), indicating its regulatory role in this gene. In addition, rs6742727 and rs7185763 were associated with transcript abundance of nearby genes GALNT3 and AC00949.2 at the TTC21B region, and IRX6 at the MMP2 region, respectively (Supplementary Table 6 ).
We used the Amazon Compute Cloud version of WGAS (Liu et al. 2016 ) to annotate T2D-ESKD-associated SNPs. Three SNPs (rs55884670, M97T at CLDN8; rs34505188, R408H at COL4A3; and rs57737815, P555R at WNK4), were annotated as missense variants by VEP (McLaren et al. 2010) , ANNOVAR (Wang et al. 2010) and SnpEff (Cingolani et al. 2012 ). In addition, rs34505188 and rs57737815 were predicted to be probably damaging by PolyPhen2 (Adzhubei et al. 2010 ). All three missense SNPs, along with rs10433935 from ARHGAP24, were located within highly conserved regions across mammalians according to their high GERP++ rejected substitutions scores (Davydov et al. 2010) . Two most recently developed functional prediction scores, CADD (Kircher et al. 2014) and DANN (Quang et al. 2015) , were evaluated for the significantly associated SNPs. Both methods predict potential pathogenicity of genetic variants by integrating a wide range of annotations into a single metric using machine learning methods (Kircher et al. 2014; Quang et al. 2015) . Again, rs34505188, rs57737815, and rs10433935 at COL4A3, WNK4, and ARHGAP24 loci, respectively, were predicted within the top pathogenic variants (0.4-8 %) in the human genome. In addition, rs55884670 (CLDN8) was ranked within the top 16 and 28 % pathogenic variants in the human genome by CADD and DANN, respectively. For regulatory region-centric annotations, rs57737815 at WNK4 overlapped with transcription factors-binding site (TFBS) of POLR2A in HepG2 cells, as well as DNase I hypersensitive site detected in two cell types. In addition, rs10433935 from ARHGAP24 overlaps with a general developmental enhancer with <5 % false discovery rate (FDR) (Erwin et al. 2014) . Full results are shown in Supplementary Table 7 .
Discussion
The contribution of genetic variants in 47 kidney structure-related genes to T2D-ESKD was evaluated in 4885 AAs with high-density genotype data which included coding and non-coding variants. Evidence of association with T2D-ESKD was observed for seven loci, including CD2AP, MMP2, TTC21B, COL4A3, NPHP3-ACAD11, CLDN8, and ARHGAP24 in single-variant analysis of either baseline or APOL1-negative models. The associated variants at COL4A3 and CLDN8 were missense mutations. All associated SNPs achieved locus-wide significance in the meta-analysis of T2D-ESKD cases and non-diabetic non-nephropathy controls, and showed no evidence of association with T2D. Gene-based and multiple bioinformatic analyses supported potential cumulative effect and functional relevance at associated loci. The most significant association was observed in two SNPs located at CD2AP in baseline model analysis. CD2-associated protein (CD2AP) is an adapter protein between membrane proteins and the actin cytoskeleton (Kirsch et al. 1999) . CD2AP is highly expressed in glomeruli, and has been associated with podocyte injury and focal segmental glomerulosclerosis (FSGS) (Shih et al. 1999; Löwik et al. 2007) . Other variants in CD2AP demonstrated suggestive associations with ESKD in Europeans with T1D (Hyvönen et al. 2013) . Together, this and other studies suggest that CD2AP variants are associated with both non-diabetic and diabetic (T1D and T2D) kidney diseases.
The SNP rs7185763 located 12-kb upstream to matrix metallopeptidase 2 (MMP2) also achieved locus-wide significance in baseline model analysis. Metallopeptidase 2 is a member of the MMP family and is involved in the degradation and turnover of extracellular matrix (ECM). Decreased expression of matrix metallopeptidase 2 in glomeruli was observed in patients with DKD, suggesting that lower expression level of MMP2 is associated with mesangial matrix expansion and T2D-ESKD (Prete et al. 1997; Mason and Wahab 2003) .
Analyses considering the impact of APOL1 renal-risk genotypes revealed further insights into genetic susceptibility to T2D-ESKD. In APOL1-negative model analysis that removed APOL1 risk genotype carriers, a low-frequency missense variant R408H (rs34505188) in type IV collagen (COL4A3) was associated with T2D-ESKD with the frequency of risk allele A being 0.033. R408H has a lower frequency in African populations (0.028), compared to European (0.069) and East Asian (0.16) based on the 1000 Genomes Project data. The alpha 3 chain in type IV collagen forms a heterotrimer with alpha 4 and alpha 5 chains, forming the major component of the GBM; it may be synthesized by podocytes (Miner 2011) . Mutations in COL4A3 are known to cause autosomal forms of Alport Syndrome (AS) and are associated with FSGS and chronic kidney disease in patients with thin basement membrane nephropathy (Kashtan 1995; Voskarides et al. 2007 ). Similar to the other five alpha chains in type IV collagen, alpha 3 contains a short amino-terminal domain, a long collagenous central domain consisting of Gly-X-Y repeats, and a non-collagenous domain. Replacement of a glycine in the Gly-X-Y repeat region is the most common mutant type of AS. These missense variants may induce kinks in folding with aberrant formation of the collagen triple helix (Prockop 1992) . R408H is located in the Gly-X-Y repeat region and a prior study suggested that this coding variant was not pathogenic for AS (Heidet et al. 2001) . However, R408H is located in a highly conserved region, and was predicted within the top 1 % of potentially pathogenic variants in the human genome by both CADD and DANN analyses. Furthermore, COL4A3 trended toward association with T2D-ESKD in the gene-based analysis with the most significant association with a rare missense mutation rs55816283 [P1109S, P = 0.00096, effect allele frequency (EAF) = 0.0008]. Taken together, multiple lines of evidence support that COL4A3 variants may be involved in ESKD susceptibility in AAs with T2D.
Another missense variant, M97T (rs55884670), in the claudin 8 gene (CLDN8) demonstrated locus-wide association with T2D-ESKD in AAs (risk G allele frequency = 0.052). This variant was not observed in nonAfrican populations based on the 1000 Genomes Project data. Claudins are integral membrane components of tight junctions that support pore and barrier functions of paracellular pathways in epithelial cells. They confer selective paracellular permeability in different segments of the renal tubule (Yu 2015) . Claudin 8 is expressed in the thin descending limb of the loop of Henle, the distal tubule, and the collecting duct. It is required for the formation of the paracellular renal chloride channel by interacting with claudin 4 (Kiuchi-Saishin et al. 2002; Li et al. 2004; Hou et al. 2010 ). Other claudins have been associated with DKD (Gaut et al. 2014; Molina-Jijón et al. 2014) ; this is the first study to report association of a CLDN8 gene variant with T2D-ESKD. Interestingly, another claudin family member CLDN14 also demonstrated a trend toward association with T2D-ESKD in the gene-based analysis. Given the vital role of claudins in the renal tubule, variants in claudin genes may impact progression of kidney disease under the stress of hyperglycemia.
Two locus-wide significant SNPs (rs74504809, rs78174962) in complete LD located in the NPHP3-ACAD11 region were associated with T2D-ESKD in APOL1-negative model. NPHP3 is involved in ciliogenesis and possibly renal tubular development (Zhou et al. 2010) . Mutations in NPHP3 cause type 3 nephronophthisis, a relatively common cause of kidney failure in children and young adults (Olbrich et al. 2003) . Both variants were located outside NPHP3, their potential regulatory role in NPHP3 gene function remains to be determined.
The SNP rs10433935 located at ARHGAP24 which encodes Rho GTPase-activating protein 24 was also associated with T2D-ESKD. Multiple lines of evidence, including eQTL analysis and WGSA annotation, suggest that rs10433935 overlaps with a highly functional region in ARHGAP24. Rho GTPase-activating protein 24 is involved in cell polarity, cell morphology, and cytoskeletal organization (Katoh and Katoh 2004) . It plays a role in podocyte differentiation and contributes to the balance of podocyte Rho A and Rac1 signaling (Akilesh et al. 2011) . Furthermore, a mutation in this gene has been associated with familial FSGS (Akilesh et al. 2011) .
Collectively, these results suggest that variation at glomerular and tubulointerstitial-related structural genes may contribute to T2D-ESKD susceptibility in AAs. DKD is a complex disease with multiple environmental risk factors and polygenic inheritance. Microvascular changes, for example, abnormal capillary permeability and retinopathy, may precede early structural glomerular changes in patients with diabetes. Thus, variations in structural genes may be manifest specifically in the kidneys, despite possible altered expression in other organs (Alpert et al. 1972; Girach and Vignati 2006) . It is noteworthy that mutations in CD2AP, COL4A3, and ARHGAP24 are known to cause the podocyte disorder FSGS (Pollak 2014) . The present findings suggest that structural kidney genetic variants may contribute to both DKD and FSGS. Alternatively, some T2D-ESKD cases might have been misclassified and had proteinuric FSGS or GBM diseases with coincident T2D. Most cases lacked a kidney biopsy; this limitation is present in virtually all large-scale genetic studies of T2D-ESKD. We carefully attempted to minimize effects of misclassification by removing patients with T2D who had other causes of kidney disease and by removing APOL1 risk genotype carriers who likely had non-diabetic kidney diseases (APOL1-negative model). The latter should lead to enrichment for true DKD cases, and additional loci may be discovered as these samples were less heterogeneous despite the smaller sample size. A similar approach led to the identification of FRMD3 association with DKD in non-APOL1 carriers (Freedman et al. 2011) . Renal tubulointerstitial fibrosis and ECM accumulation have great impact on progression of DKD, as well as on other etiologies of nephropathy. Our results are consistent with variation in tubulointerstitiumrelated structural genes, such as MMP2, NPHP3, TTC21B, CLDN8, CLDN14, and WNK4 contributing to interstitial injury and fibrosis in patients susceptible to DKD. This study has limitations. As stated, it is difficult to fully exclude all cases misclassified as DKD due to the frequent lack of kidney biopsy material. However, removing patients with ESKD attributed to non-diabetic etiologies, as well as excluding APOL1 renal-risk allele carriers, should minimize misclassification despite considerable reductions in power. An additional limitation is that many other kidney structure-related genes, for instance SLC5A2, which plays a role in tubuloglomerular feedback and hyperfiltration injury (Škrtić and Cherney 2015) , could not be included due to the gene selection criteria. Higher density genetic data remain necessary to thoroughly examine these genes. Moreover, we lack prospective follow-up data to investigate genetic contributions to the progression of kidney disease in diabetic patients; this could be a powerful analysis to understand the dynamics of DKD. Finally, we did not adjust for several well-established DKD risk factors in our analyses, including blood pressures, degrees of albuminuria, body mass index, HbA 1c , or medication usage, because these change frequently over time as disease progresses.
Conclusion
This is the first study to comprehensively survey the genetic effects of kidney structure-related loci in T2D-ESKD susceptibility in the AA population. Using high-density genetic data and a multi-stage study design, strong genetic associations were identified between several kidney structure genes and T2D-ESKD risk. T2D-ESKD-associated variants at COL4A3, CLDN8, and ARHGAP24 were potentially pathogenic. Future functional studies are warranted to illustrate the potential mechanisms underlying the effect of these newly identified genetic associations.
